BRAF and non-small cell lung carcinoma: In a trial evaluating vemurafenib in patients with BRAF-mutant advanced NSCLC, median PFS was 1.9 months (95% CI, 1.5–3.9) and 5.4 months (95% CI, 3.8–7.2) in patients with (n = 26) and without (n = 89) baseline BMs11.